Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Open Label, Uncontrolled, Phase 2a Clinical Trial Evaluating the Safety and Efficacy of the Addition of Ibrutinib to Venetoclax Through a MRD-guided Approach in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia (CLL)

NCT04754035 is registered in ClinicalTrials.gov with Paolo Ghia as lead sponsor.

NCT NCT04754035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04754035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Open Label, Uncontrolled, Phase 2a Clinical Trial Evaluating the Safety and Efficacy of the Addition of Ibrutinib to Venetoclax Through a MRD-guided Approach in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia (CLL)
Lead sponsor
Paolo Ghia
Phase
Phase 2
Overall status
Unknown status
Start date
November 8, 2017
Completion date
September 1, 2025
Enrollment
31 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia